Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of trametinib and during the study
Use of other investigational drugs within  days or at least  half-lives (whichever is shorter) before study drug administration
Use of an investigational drug within  days or  half-lives (whichever is shorter) prior to the first dose of TGR-; for investigational drugs for which  half-lives is less than  days, a minimum of  days between termination of the investigational drug and administration of TGR- is required
Taken an investigational drug within  days or  half-lives (minimum  days), whichever is shorter, prior to study day 
Patients who are receiving any other investigational agents have received any other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of study treatment and during the study
Use of anti-cancer treatment drug =<  days or  half-lives (whichever is shorter) prior to the first dose of AZD; for drugs for which  half-lives is =<  days, a minimum of  days between termination of the prior treatment and administration of AZD treatment is required
Use of an investigational drug ? days or  half-lives (whichever is shorter) prior to the first dose of orteronel, or concurrent treatment. For investigational drugs for which  half-lives is less than  days, a minimum of  days between termination of the investigational drug and administration of orteronel is required.
Use of an investigational drug within  days or  half-lives (whichever is shorter) prior to the first dose of X-. A minimum of  days between treatment and X- and  days between ALK TKI and X-.
Use of other investigational, chemotherapeutic or targeted drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of talimogene laherparepvec and during the study are ineligible
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of trametinib and during the study
Administration of an investigational drug within  days or  half-lives, whichever is shorter, preceding the first dose of study treatment(s) in this study.
Use of other investigational drugs (drugs not marketed for any indication) within  days or at least  half-lives (whichever is shorter) before study drug administration
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of trametinib and during the study
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of study drug(s) and during the study
Use of an investigational drug within  days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within  days of receiving the first dose of study drugs. Prior BCMA targeted therapy.
Use of anti-cancer treatment drug =<  days or  half-lives (whichever is shorter) prior to the first dose of AZD; for drugs for which  half-lives is =<  days, a minimum of  days between termination of the prior treatment and administration of AZD treatment is required
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of talimogene laherparepvec (T-VEC) and during the study
Use of other investigational drugs within  days preceding the first dose of trametinib and during the study
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of study treatment and during the study
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of study treatment and during the study
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of trametinib or standard of care agent
Administration of an investigational drug within  days or  half-lives, whichever is shorter with a minimum of  days preceding the first dose of study treatment(s) in this study.
At least  days or  half-lives (whichever is shorter) since prior investigational anti-cancer drugs. A minimum of  days between termination of the investigational drug and administration of VAL- is required.
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) either preceding the first dose of ganetespib or during the study period
Use of other investigational drugs within  days preceding the first dose of vemurafenib during this study
Receiving any other investigational agent(s) within  days or  half-lives (whichever is shorter) prior to the first dose of study drug; a minimum of  days between termination of the investigational drug and administration of study drug is required
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of trametinib/GSK and during the study
Administration of an investigational drug within  days or  half-lives, whichever is shorter preceding the first dose of study treatment(s) in this study.
. Use of an investigational drug within  days or  half-lives (whichever is shorter) prior to the first dose of study drug. A minimum of  days between termination of the investigational drug and administration of the study treatment is required. In addition, any drug-related toxicity except alopecia should have recovered to grade  or less.
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of study therapy and during the study
Received an investigational anti-cancer drug within weeks, or within  half-lives (whichever is shorter) of the first dose of study drug(s). A minimum of  days must have passed between the last dose of prior investigational agent and the first dose of study drug.
Use of other investigational drugs within  days preceding the first dose of vemurafenib on this study.
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of trametinib alone or with GSK and during the study
At least  days or  half-lives (whichever is shorter) since prior investigational anti-cancer drugs. A minimum of  days between termination of the investigational drug and administration of DAG is required
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of talazoparib and during the study
Use of an investigational drug within  days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within  days of receiving the first dose of study drug.
Use of other investigational drugs within  days (or five half-lives, whichever is shorter; with a minimum of  days from the last dose) preceding the first dose of trametinib and during the study
Use of any investigational drug within  days or five half-lives, whichever is shorter, prior to the first dose of study medication; a minimum of  days between termination of the investigational drug and treatment with study medication is required
Use of an investigational anti-cancer drug within  days or five half-lives, whichever is shorter, prior to the first dose of GSK; a minimum of  days between termination of the investigational drug and administration of GSK is required; in addition, any drug-related toxicity should have recovered to grade  or less
